James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Bank of America Corp (BAC) Stock Could Take Flight Tomorrow

Bank of America (BAC) reports Q4 earnings on Friday morning. Anyone interested in BAC stock should watch out for these three items.

3 Charts That Show Why Sprint Corp (S) Stock Looks REALLY Grim

If you own Sprint stock or are thinking about buying it, these three reality checks may change your mind. Here's what you need to know.

Why Juniper Networks, Inc. (JNPR), Supervalu Inc. (SVU) and Bristol-Myers Squibb Co (BMY) Are 3 of Today’s Worst Stocks

Juniper Networks (JNPR), Bristol-Myers Squibb (BMY) and Supervalu (SVU) lost their uphill battles they were forced to fight on Wednesday.

Why Williams Companies Inc (WMB), Fitbit Inc (FIT) and Merrimack Pharmaceuticals Inc (MACK) Are 3 of Today’s Worst Stocks

Fitbit (FIT), Williams Companies (WMB) and Merrimack Pharmaceuticals (MACK) woke up on the wrong side of the bed on Tuesday.

7 Blue-Chip Dividend Stocks That Are Dead Weight Right Now

Most blue-chip dividend stocks have adjusted for the prospect of rising interest rates, but a few more are facing additional problems.